Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

ClinicalTrials.gov ID: NCT01966471

Public ClinicalTrials.gov record NCT01966471. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer

Study identification

NCT ID
NCT01966471
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
1,846 participants

Conditions and interventions

Conditions

Interventions

  • 5-Fluorouracil Drug
  • Cyclophosphamide Drug
  • Docetaxel Drug
  • Doxorubicin Drug
  • Epirubicin Drug
  • Paclitaxel Drug
  • Pertuzumab Drug
  • Trastuzumab Drug
  • Trastuzumab Emtansine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 30, 2014
Primary completion
Nov 26, 2019
Completion
Jun 3, 2021
Last update posted
Jun 13, 2022

2014 – 2021

United States locations

U.S. sites
50
U.S. states
23
U.S. cities
47
Facility City State ZIP Site status
HonorHealth Research Institute - Bisgrove Scottsdale Arizona 85258
Kaiser Permanente - Oakland Oakland California 94611
Kaiser Permanente - Roseville; Oncology Pharmacy Roseville California 95661
Kaiser Permanente - Sacramento; Oncology Pharmacy Sacramento California 95814
UC Davis Cancer Center; Oncology Sacramento California 95817
Southern California Kaiser Permanente San Diego California 92108
Kaiser Permanente - San Jose San Jose California 95119
Kaiser Permanente - San Leandro San Leandro California 94577
Kaiser Permanente - South SF; Oncology Clinical trials South San Francisco California 94080
Stanford University School of Medicine Stanford California 94305-5151
Kaiser Permanente - Vallejo Vallejo California 94589
Kaiser Permanente - Walnut Creek; Oncology Pharmacy Walnut Creek California 94596
Holy Cross Hospital Fort Lauderdale Florida 33308
Florida Cancer Specialists; SCRI Fort Myers Florida 33901
Florida Cancer Specialists; Saint Petersburg St. Petersburg Florida 33719
University Cancer & Blood Center, LLC; Research Athens Georgia 30607
Georgia Cancer Specialists Atlanta Georgia 30341
Central Georgia Cancer Care PC Macon Georgia 31201
Quincy Medical Group; Canc Ctr at Blessing Hosp Quincy Illinois 62301
Carle Cancer Center Urbana Illinois 61801
Indiana University Indianapolis Indiana 46202
Cancer Center of Kansas Wichita Kansas 67214-3728
Anne Arundel Health System Research Instit-Annapolis Oncology Ctr Annapolis Maryland 21401
Mercy Medical Center Baltimore Maryland 21202
Dana Farber Cancer Inst. Boston Massachusetts 02115
Beth Israel Deaconess Med Ctr Boston Massachusetts 02215
Karmanos Cancer Institute.. Detroit Michigan 48201
Henry Ford Hospital; Hematology Oncology Detroit Michigan 48202
US oncology research at Minnesota Oncology Saint Paul Minnesota 55102
Mercy Medical Research Institute Springfield Missouri 65807
Dartmouth Hitchcock Med Center Lebanon New Hampshire 03756
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08901
Memorial Sloan-Kettering Cancer Center Commack New York 11725
ProHEALTH Care Associates LLP Lake Success New York 11042
Levine Cancer Institute Charlotte North Carolina 28204
Duke University Medical Center Durham North Carolina 27710
Cone Health Cancer Center Greensboro North Carolina 27403
Oncology Hematology Care Inc Cincinnati Ohio 45242
Mercy Clinic Oklahoma Communties, Inc Oklahoma City Oklahoma 73120
Magee-Woman's Hospital Pittsburgh Pennsylvania 15213
SCRI Tennessee Oncology Chattanooga Chattanooga Tennessee 37404
West Clinic Germantown Tennessee 38138
Thompson Cancer Survival Center Knoxville Tennessee 37916-2305
Sarah Cannon Cancer Center - Tennessee Oncology, Pllc Nashville Tennessee 37203
The Center for Cancer and Blood Disorders - Fort Worth Fort Worth Texas 76104
Wellmont Medical Associates Bristol Virginia 24201
University of Virginia Health System; Hematology/Oncology Division Charlottesville Virginia 22908
Virginia Commonwealth University - Massey Cancer Center Richmond Virginia 23298
Blue Ridge Cancer Care - Salem Salem Virginia 24153
University of Washington Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 245 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01966471, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 13, 2022 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01966471 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →